Literature DB >> 8853014

Manipulation of the Semliki Forest virus genome and its potential for vaccine construction.

G J Atkins1, B J Sheahan, P Liljeström.   

Abstract

The Semliki Forest virus (SFV) expression vector consists of a plasmid based on the SFV infectious clone. Foreign genes may be inserted into the structural coding region, transcribed as RNA, and expressed in cell culture after transfection. RNA containing inserted sequences may be packaged into virions using a helper systems. This allows efficient infection and expression without chemical transfection, but only one round of multiplication is possible. The biosafety of the system has been increased by the introduction of multiple mutations, specifying a maturation defect, into the helper. Potential vaccines can be constructed by insertion of genes coding for antigenic proteins into the vector. Following insertion of the influenza virus nucleoprotein (NP) into the SFV vector, immunity was induced following injection of packaged or naked RNA into mice. The SFV vector is a "suicide" expression vector that has great potential for the construction of vaccines for both human and veterinary use.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8853014     DOI: 10.1007/BF02762410

Source DB:  PubMed          Journal:  Mol Biotechnol        ISSN: 1073-6085            Impact factor:   2.695


  24 in total

1.  Nucleotide sequence of cdna coding for Semliki Forest virus membrane glycoproteins.

Authors:  H Garoff; A M Frischauf; K Simons; H Lehrach; H Delius
Journal:  Nature       Date:  1980-11-20       Impact factor: 49.962

2.  The capsid protein of Semliki Forest virus has clusters of basic amino acids and prolines in its amino-terminal region.

Authors:  H Garoff; A M Frischauf; K Simons; H Lehrach; H Delius
Journal:  Proc Natl Acad Sci U S A       Date:  1980-11       Impact factor: 11.205

3.  Isolation and preliminary characterization of Semliki Forest virus mutants with altered pathogenicity for mouse embryos.

Authors:  A M Hearne; M A O'Sullivan; G J Atkins
Journal:  J Gen Virol       Date:  1987-01       Impact factor: 3.891

Review 4.  The alphaviruses: gene expression, replication, and evolution.

Authors:  J H Strauss; E G Strauss
Journal:  Microbiol Rev       Date:  1994-09

5.  Semliki Forest virus expression system: production of conditionally infectious recombinant particles.

Authors:  P Berglund; M Sjöberg; H Garoff; G J Atkins; B J Sheahan; P Liljeström
Journal:  Biotechnology (N Y)       Date:  1993-08

6.  Investigations into yellow fever virus and other arboviruses in the northern regions of Kenya.

Authors:  B E Henderson; D Metselaar; G B Kirya; G L Timms
Journal:  Bull World Health Organ       Date:  1970       Impact factor: 9.408

7.  A new generation of animal cell expression vectors based on the Semliki Forest virus replicon.

Authors:  P Liljeström; H Garoff
Journal:  Biotechnology (N Y)       Date:  1991-12

8.  A significantly improved Semliki Forest virus expression system based on translation enhancer segments from the viral capsid gene.

Authors:  E M Sjöberg; M Suomalainen; H Garoff
Journal:  Biotechnology (N Y)       Date:  1994-11

9.  A single amino acid change in the E2 spike protein of a virulent strain of Semliki Forest virus attenuates pathogenicity.

Authors:  G M Glasgow; H M Killen; P Liljeström; B J Sheahan; G J Atkins
Journal:  J Gen Virol       Date:  1994-03       Impact factor: 3.891

10.  Expression of HIV-1 envelope glycoproteins by Semliki Forest virus vectors.

Authors:  N L Paul; M Marsh; J A McKeating; T F Schulz; P Liljeström; H Garoff; R A Weiss
Journal:  AIDS Res Hum Retroviruses       Date:  1993-10       Impact factor: 2.205

View more
  6 in total

1.  Cancer therapy using a self-replicating RNA vaccine.

Authors:  H Ying; T Z Zaks; R F Wang; K R Irvine; U S Kammula; F M Marincola; W W Leitner; N P Restifo
Journal:  Nat Med       Date:  1999-07       Impact factor: 53.440

2.  Immunogene therapy of recurrent glioblastoma multiforme with a liposomally encapsulated replication-incompetent Semliki forest virus vector carrying the human interleukin-12 gene--a phase I/II clinical protocol.

Authors:  H Ren; T Boulikas; K Lundstrom; A Söling; P C Warnke; N G Rainov
Journal:  J Neurooncol       Date:  2003 Aug-Sep       Impact factor: 4.130

Review 3.  Viral vectors for veterinary vaccines.

Authors:  M Sheppard
Journal:  Adv Vet Med       Date:  1999

Review 4.  Viral vectors for malaria vaccine development.

Authors:  Shengqiang Li; Emily Locke; Joseph Bruder; David Clarke; Denise L Doolan; Menzo J E Havenga; Adrian V S Hill; Peter Liljestrom; Thomas P Monath; Hussein Y Naim; Christian Ockenhouse; De-chu C Tang; Kent R Van Kampen; Jean-Francois Viret; Fidel Zavala; Filip Dubovsky
Journal:  Vaccine       Date:  2006-08-01       Impact factor: 3.641

Review 5.  Messenger RNA vaccines for cancer immunotherapy: progress promotes promise.

Authors:  Amanda L Huff; Elizabeth M Jaffee; Neeha Zaidi
Journal:  J Clin Invest       Date:  2022-03-15       Impact factor: 19.456

Review 6.  Reverse genetics of measles virus and resulting multivalent recombinant vaccines: applications of recombinant measles viruses.

Authors:  M A Billeter; H Y Naim; S A Udem
Journal:  Curr Top Microbiol Immunol       Date:  2009       Impact factor: 4.291

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.